Carfilzomib (CFZ), a second-generation proteasome inhibitor, offers potent activity against multiple myeloma (MM) but suffers from rapid clearance, short half-life ( 85%), cytotoxicity (> 90%) in multiple myeloma cells (MM cells), and high tumor growth inhibition(> 85%) compared to non-conjugated nanocomposites. This work highlights the novelty of combining proteasome inhibition with anti-CD38 targeting in a single nano-formulation, offering prolonged drug retention, improved tumor-specific delivery, and reduced systemic limitations of CFZ. The Ab-CFZ-PCL-NPs establish a promising theragnostic platform for advancing precision therapies in multiple myeloma beyond conventional nanoparticle approaches.
Mishra et al. (Fri,) studied this question.